Loading
A thin slice of a tumour, kept alive for a few days, still contains the immune cells and scaffolding that lab-grown cells lose. Drugs can be tested on it directly.
Precision-cut tumour slices preserve native architecture, stroma, vasculature remnants and resident immune cells for several days, and have been used to measure responses to chemotherapy, targeted agents and immunotherapy with imaging and single-cell readouts. They avoid the selection and adaptation that occur during organoid derivation, at the cost of a short experimental window.
Shares Functional (ex vivo) drug testing, Single-cell & spatial profiling, Patient-derived organoids, Lab models that fail to predict what happens in patients.
Shares Curesponse, Estimation of clinical trial success rates and related parameters, Functional (ex vivo) drug testing, Patient-derived organoids.
Shares Estimation of clinical trial success rates and related parameters, Functional (ex vivo) drug testing, Lab models that fail to predict what happens in patients.
Shares Estimation of clinical trial success rates and related parameters, Functional (ex vivo) drug testing, Patient-derived organoids, Lab models that fail to predict what happens in patients.
Shares Estimation of clinical trial success rates and related parameters, Patient-derived organoids, Lab models that fail to predict what happens in patients.
Shares Estimation of clinical trial success rates and related parameters, Functional (ex vivo) drug testing, Lab models that fail to predict what happens in patients.
Shares Estimation of clinical trial success rates and related parameters, Patient-derived organoids, Lab models that fail to predict what happens in patients.
Shares Estimation of clinical trial success rates and related parameters, Functional (ex vivo) drug testing, Patient-derived organoids, Lab models that fail to predict what happens in patients.